INS and prostate carcinoma: According to GLOBOCAN 2018, prostate cancer is the third most prevalent cancer in both men and women, as well as the second most common cancer in males worldwide.[6,7] Obesity at a young age delays puberty and may lead to a lower lifetime exposure to insulin-like growth factor 1, which may influence prostate cancer development later in life.[8,9] Elevated lipid levels and lipid signaling, inflammatory responses, insulin resistance, and adipokines have all been proposed as pathways to explain the association between cancer and obesity.